SOGA1抗体;SOGA1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12992(SOGA1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

SOGA1 (Suppressor of Glucose, Autophagy Associated 1) is a protein implicated in metabolic regulation and autophagy. It was initially identified as a tumor suppressor due to its role in inhibiting the mammalian target of rapamycin (mTOR) pathway, a key regulator of cell growth and autophagy. SOGA1 is encoded by the SOGA1 gene, which is evolutionarily conserved and expressed in various tissues, including the liver, brain, and skeletal muscle. The protein interacts with components of the insulin signaling pathway, suggesting a connection to glucose metabolism and insulin resistance. Research has shown that SOGA1 expression is downregulated in certain cancers, such as colorectal and breast cancer, correlating with disease progression and poor prognosis.

SOGA1 antibodies are critical tools for studying its function, localization, and expression patterns. These antibodies are typically developed against specific epitopes, such as the N-terminal or C-terminal regions of the human SOGA1 protein, and validated for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Studies using SOGA1 antibodies have revealed its cytoplasmic localization and involvement in stress-induced autophagy. Additionally, SOGA1 has been linked to neurodegenerative diseases, where dysregulated autophagy contributes to pathology. The antibody’s specificity is often confirmed using knockout cell lines or siRNA-mediated silencing. Ongoing research aims to clarify SOGA1’s precise molecular mechanisms and therapeutic potential in metabolic disorders and cancer.